Contribución de la ecografía de punto de atención por parte del médico de emergencias para descartar la obstrucción del intestino delgado: un estudio de diagnóstico y multicéntrico (OCCLUS-POCUS)
Small Bowel Obstruction (SBO) is a frequent pathology in the emergency department (ED). Diagnosis is currently based on abdominal CT scan (CT). Moreover, CT is warranted to determine the therapeutic strategy in patients with SBO which could include medical treatment; surgical intervention or both. However, CT is associated with drawbacks such as radiation exposure, increased cost and ED length-of-stay.
In a prospective observational study, a SBO was excluded by CT in 45% [95%CI: 37-53] of patients. There is, thus, a need for improving the appropriateness of CT-scan for suspected SBO.
A recent meta-analysis showed that Point of care ultrasound (POCUS) had a good diagnostic accuracy (sensitivity 83% [95%CI 71.7%-90.4%]), specificity 93% [95%CI 55.3%-99.3%]). Another meta-analysis found rather similar results (sensitivity 83% [(95% CI 89.0% to 94.7%], specificity 96,6% [95% CI 88.4% to 99.1%]).
In order to improve the negative predictive value of POCUS for its implementation as a rule-out strategy, CHU of Nantes emergency unit studied the combination of POCUS with Gestalt pre-test probability of SBO determined by the emergency physician. This SBO probability classified the patients as low, moderate or high risk of SBO. In patients with low or moderate Gestalt probability, CHU of Nantes emergency unit found that this combined strategy had a sensitivity of 100% [95% CI: 88-100] and NPV 100% [92-100%].
By (i) focusing on patients with a low or moderate Gestalt clinical probability and (ii) increasing the number of patients included, CHU of Nantes emergency unit intends to demonstrate that POCUS is able to exclude SBO in this population. This would avoid unnecessary CT and thus lower costs, ED length-of-stay and hospital radiologists workload.
A POCUS will be performed followed by a CT (gold standard). The main objective will be the ability of POCUS to rule-out SBO in patients with low or moderate Gestalt clinical probability.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Small Bowel Obstruction (SBO) is a frequent pathology, leading to admissions to emergency departments (ED). Diagnosis is currently based on an abdominal CT scan (CT). However, CT is associated with drawbacks such as radiation exposure, increased cost and ED length-of-stay.
A recent meta-analysis including 1178 patients showed that Point of care ultrasound (POCUS) had a good diagnostic accuracy (sensitivity 83% [95%CI 71.7%-90.4%]), specificity 93% [95%CI 55.3% -99.3%]). Another meta-analysis with 433 patients, found rather similar results: sensitivity 83% [95% CI 89.0% to 94.7%], specificity 96,6% [95% CI 88.4% to 99.1%]).
Since CT is almost warranted to guide the treatment strategy, which could include surgery, medical treatment or both, CHU of Nantes emergency unit explored a different approach focusing on POCUS rule-out ability. This study also introduced the notion of SBO Gestalt probability which is a global clinical evaluation by the physician. Gestalt probability has mainly been explored in patients with suspected pulmonary embolism and was found as effective as clinical prediction rules. It is used in the routine clinical evaluation of patient with suspicion of pulmonary embolism. When applied to patients with SBO suspicion, the physician chooses between low, moderate or high risk of SBO. Based on CT results, prevalence of SBO based on Gestalt probability were 21%, 45% and 87% in the low, moderate and high risks, respectively.
Our team studied POCUS with the following items that were searched in the whole abdomen divided into nine zones: dilated incompressible fluid-filled intestinal loop (>25 mm) with back-and-forth fluid movement. When at least one of these signs was present in one zone, the SBO was highly suspected. As it was an observational study, a CT was performed in all patients and was the gold standard. This approach was associated with a POCUS sensitivity in the whole population of 99% [95% CI: 93-99.8] [2]. POCUS would thus have a role in patients with low and moderate SBO risks because the prevalence of SBO was major in the high risk Gestalt probability category of patients, and thus CT is the only imaging needed in these latter. Furthermore, in patients with low or moderate probability, the sensitivity was 100% [95% CI: 88-100] In previous studies, the sensitivity was not able to exclude SBO with sufficient security since the lower 95% confidence interval margin was near 90%. By (i) focusing on patients with a low or moderate clinical Gestalt probability and (ii) increasing the number of patients, CHU of Nantes emergency unit intends to demonstrate that POCUS should be able to safely exclude SBO in this population.
In case of positive results, the diagnostic strategy in case of SBO suspicion could be modified in: firstly, assess the clinical Gestalt probability; secondly perform a POCUS in patients with low or moderate Gestalt probability and thirdly, prescribe a CT only for patients with high clinical probability or presence of POCUS signs of SBO. This would avoid unnecessary CT and thus lower patient's.
exposure, costs, ED length-of-stay and radiologist workload. A study performed in the USA simulated a POCUS first approach in patients with suspected SBO and found that it could save ED length of stay, radiation and money. In France in 2017, about ¾ of ED were equipped with ultrasound machines and half of the emergency physicians were trained in POCUS. Furthermore, SBO detection is easily performed: in our study, the operator self-assessed ultrasound experience was beginner or intermediate for 59% of patients. In case of positive results, this technique would be largely deployed.
Inclusion criteria will be patients with low or moderate Gestalt clinical probability of SBO. A POCUS will be performed followed by a CT (gold standard). This CT will be realized and interpreted blindly from the POCUS results. The main objective will be the ability of POCUS to rule-out SBO in patients with low or moderate Gestalt clinical probability
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Philippe LE CONTE Professor LE CONTE, Professor
- Número de teléfono: +33 0240083934
- Correo electrónico: philippe.leconte@chu-nantes.fr
Ubicaciones de estudio
-
-
-
Clermont-Ferrand, Francia, 63100
- Reclutamiento
- Chu Clermont-Ferrand Hopital Gabriel Montpied
-
Contacto:
- Christophe Perrier, Doctor
- Número de teléfono: +33 04 73 754 754
- Correo electrónico: cperrier@chu-clermontferrand.fr
-
Investigador principal:
- Christophe PERRIER, Doctor
-
Eaubonne, Francia, 95600
- Reclutamiento
- Ghem Groupe Hospitalier Eaubonne Montmorency Simone Veil
-
Contacto:
- Maxime GAUTIER, Doctor
- Número de teléfono: +33 01 34 06 67 55
- Correo electrónico: maxime.gautier@ch-simoneveil.fr
-
Investigador principal:
- Maxime GAUTIER, Doctor
-
La Roche-sur-Yon, Francia, 85925
- Reclutamiento
- CHD Vendée
-
Contacto:
- François BRAU, Doctor
- Número de teléfono: +33 02 51 44 61 61
- Correo electrónico: francois.brau@ght85.fr
-
Investigador principal:
- François BRAU, Doctor
-
Luçon, Francia, 85407
- Reclutamiento
- CHD Vendée, Luçon
-
Investigador principal:
- François BRAU, Doctor
-
Contacto:
- François BRAU, Doctor
- Número de teléfono: +33 02 51 44 62 05
- Correo electrónico: francois.brau@ght85.fr
-
Marseille, Francia, 13005
- Reclutamiento
- Ap-Hm Hopital La Timone
-
Contacto:
- Thibaut MARKARIAN, Doctor
- Número de teléfono: +33 04 91 38 00 00
- Correo electrónico: thibaut.markarian@ap-hm.fr
-
Investigador principal:
- Thibaud MARKARIAN, Doctor
-
Melun, Francia, 77000
- Reclutamiento
- Ghsif Groupe Hospitalier Sud Ile de Franc _ Ch Melun
-
Contacto:
- Yousra GUETARI, Doctor
- Número de teléfono: +33 01 81 74 24 03
- Correo electrónico: yousra.guetari@ghsif.fr
-
Investigador principal:
- Yousra GUETARI, Doctor
-
Montaigu, Francia, 85600
- Reclutamiento
- CHD Vendée, Montaigu
-
Investigador principal:
- François BRAU, Doctor
-
Contacto:
- François BRAU, Doctor
- Número de teléfono: +33 02 51 44 62 05
- Correo electrónico: francois.brau@ght85.fr
-
Nantes, Francia, 44000
- Reclutamiento
- CHU Nantes
-
Contacto:
- Philippe LE CONTE, Professor
- Número de teléfono: +33 +33240084654
- Correo electrónico: philippe.leconte@chu-nantes.fr
-
Investigador principal:
- Philippe LE CONTE, Professor
-
Nantes, Francia, 44200
- Reclutamiento
- Le Confluent
-
Contacto:
- Christophe BERRANGER, Doctor
- Número de teléfono: +33 02 28 25 56 51
- Correo electrónico: christophe.berranger@groupeconfluent.fr
-
Investigador principal:
- Christophe BERRANGER, Doctor
-
Nîmes, Francia, 30029
- Reclutamiento
- CHU CAREMEAU - Nimes
-
Contacto:
- Laura MERCIER, Doctor
- Número de teléfono: +33 04 66 68 30 50
- Correo electrónico: laura.mercier@chu-nimes.fr
-
Investigador principal:
- Laura MERCIER, Doctor
-
Paris, Francia, 75012
- Reclutamiento
- AP-HP Est Parisien _ ST-ANTOINE
-
Contacto:
- Agathe BEAUVAIS, Doctor
- Número de teléfono: +33 01 71 97 00 60
- Correo electrónico: agathe.beauvais@aphp.fr
-
Investigador principal:
- Agathe BEAUVAIS, Doctor
-
Paris, Francia, 75014
- Reclutamiento
- P-HP Paris Centre - COCHIN
-
Contacto:
- Jérôme BOKOBZA, Doctor
- Número de teléfono: +33 01 58 41 27 22
- Correo electrónico: Jerome.bokobza@aphp.fr
-
Investigador principal:
- Jérôme BOKOBZA, Doctor
-
Poitiers, Francia, 86021
- Reclutamiento
- Chru Poitiers
-
Contacto:
- Jérémy GUENEZAN, Doctor
- Número de teléfono: +33 05 49 44 44 44
- Correo electrónico: jeremy.guenezan@chu-poitiers.fr
-
Investigador principal:
- Jérémy GUENEZAN, Doctor
-
Saint-Lô, Francia, 50009
- Reclutamiento
- CH MEMORIAL - Saint Lô
-
Contacto:
- Félix AMIOT, Doctor
- Número de teléfono: +33 02 33 06 30 47
- Correo electrónico: felix.amiot@ch-stlo.fr
-
Investigador principal:
- Félix AMIOT, Doctor
-
Saint-Nazaire, Francia, 44600
- Reclutamiento
- CH Saint-Nazaire
-
Contacto:
- Sylvain AMIMER, Doctor
- Número de teléfono: +33 02 72 27 81 87
- Correo electrónico: s.amimer@ch-saintnazaire.fr
-
Investigador principal:
- Sylvain AMIMER, Doctor
-
Sélestat, Francia, 67600
- Reclutamiento
- Groupe Hospitalier Selestat Obernai (Ghso)
-
Contacto:
- Mathieu OBERLIN, Doctor
- Número de teléfono: +33 03 88 20 50 60
- Correo electrónico: mathieu.oberlin@ghso.fr
-
Investigador principal:
- Mathieu OBERLIN, Doctor
-
Toulouse, Francia, 31300
- Reclutamiento
- Hopital PURPAN CHU Toulouse
-
Contacto:
- Frederic BALEN, Doctor
- Número de teléfono: +33 05 61 32 22 71
- Correo electrónico: balen.f@chu-toulouse.fr
-
Investigador principal:
- Frederic BALEN, Doctor
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Patients with suspected SBO, with low or moderate Gestalt probability and who meet the inclusion criteria (and without any non inclusion criteria)
Descripción
Inclusion Criteria:
- Major patient (age > 18 years old), no upper limit
- Patient admitted to the ED with suspected SBO (abdominal pain, vomiting, cessation of gas and feces...)
- Low or moderate pretest Gestalt clinical probability
- Patient able to understand protocol and express agreement
- Oral non-opposition given
Exclusion Criteria:
- Patient under legal guardianship
- Pregnant women
- Nursing mothers
- Patient who does not speak or understand French
- Patient without a health insurance plan
- Patient who already had imaging confirming the diagnosis
- Patient who participates simultaneously in any interventional study focused on abdominal pain before POCUS and CT realization
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Número de grupos/cohortes
Cohortes e Intervenciones
Grupo / CohorteGrupo / Cohorte |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
POCUS
Point of care ultrasound in Small bowel obstruction in Emergency Medicine, |
OCCLUS-POCUS will include patients with suspected SBO, with low or moderate Gestalt probability who meet the inclusion criteria During the patient's visit to the ED, the investigating physician will present the study and the importance of evaluating the value of POCUS in the diagnosis of exclusion of SBO. Once oral non-opposition to the study has been obtained, the participation of the patient lasts 28 days. POCUS is performed only for patients with low or moderate Gestalt probability. It will be performed by trained emergency physicians (EP) using a curvilinear probe . After POCUS realization, the EP will:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Estimate the ability of POCUS to rule-out SBO in patients with low or moderate Gestalt clinical probability
Periodo de tiempo: Day 1
|
Evaluation of the negative predictive value (NPV) of point of care ultrasound (POCUS) in patients with suspected Small Bowel Obstruction (SBO) (number of patients with negative POCUS in patients without SBO according to the CT (gold standard) divided by total patients with negative POCUS) |
Day 1
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
1/ Diagnostic accuracy of POCUS for the diagnosis of SBO
Periodo de tiempo: Day 1
|
1/ Sensitivity, specificity, positive predictive value of POCUS determined from POCUS and CT results. |
Day 1
|
|
2/ Estimation of time between POCUS and CT report
Periodo de tiempo: Day 1
|
2/ Time between point of care ultrasound and CT report |
Day 1
|
|
3a/ Description of "false negative" (exclusion of SBO diagnosis by POCUS, but diagnosis of SBO by CT)
Periodo de tiempo: Day 1
|
3a/ Characteristics associated with false negative (BMI, sex, age, physician's experience, physician's evaluation of POCUS difficulty on a numerical scale from 0 to 10) |
Day 1
|
|
3b/ Description of "false positive" (SBO diagnosis by POCUS, but diagnosis of SBO excluded by CT)
Periodo de tiempo: Day 1
|
3b/ Characteristics associated with false positive (BMI, sex, age, physician's experience, physician's evaluation of POCUS difficulty on a numerical scale from 0 to 10) |
Day 1
|
|
4/ Description of patients with a final diagnosis other than SBO
Periodo de tiempo: Day 1
|
4/ Patients' characteristics with other diagnosis than SBO (BMI, sex, age, final diagnosis) |
Day 1
|
|
5/ Physician's assessment of the POCUS procedure
Periodo de tiempo: Day 1
|
5/ Duration in minutes of POCUS and difficulty of clinical POCUS estimated by the operator on a numerical scale named "operator difficulty of clinical POCUS realization" from 0 to 10 (0 being the lower and 10 the higher score) |
Day 1
|
|
6a/ Physician intention to prescribe CT even if POCUS showed no SBO
Periodo de tiempo: Day 1
|
6a/ Number of CT which would have been prescribed for acute abdominal pain |
Day 1
|
|
6b/ Reason for which CT would have been realized
Periodo de tiempo: Day 1
|
6b/ Reason for requesting a CT in spite of exclusion of a diagnosis of SBO (poor echogenicity, lack of confidence in its realization, other diagnostic suspicion requiring a CT scan …) |
Day 1
|
|
7/ Follow-up of patients
Periodo de tiempo: Day 28
|
Phone call at Day 28 to establish the health status in relation to the previous reason for emergency consultation, to know if a second visit to emergency department for same reason within 7 days of primary consultation happened, and/or if another hospitalization within 28 days happened) |
Day 28
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
Otros números de identificación del estudio
- RC24_0388
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .